http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2750452-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40765ca9a78b54a8a76f781d159ad145 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00 |
| filingDate | 2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eafd9b93ec6600bf7e3c4551ff18096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63027f56d6f7b645aa17f6d6709a5347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_314786c4a77c4e9cba6c0960263e7a2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbc26c3577103a2b2e6ea332e4edb3fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3607e5786186af7fbfd87ba95ed2d9e4 |
| publicationDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2750452-T3 |
| titleOfInvention | Quinoline derivatives as bromodomain inhibitors |
| abstract | A compound of Formula IC: ** Formula ** wherein: R2 is selected from the group consisting of hydrogen, halo, C1-4 haloalkyl, cyano, NR2aR2b, carboxyl, C (O) NR2aR2b, OR2c, C1-6 alkyl, non substituted or substituted, unsubstituted or substituted C3-12 cycloalkyl, unsubstituted or substituted C3-12 heterocycloalkyl, unsubstituted or substituted C3-12 aryl, and substituted or unsubstituted C3-12 heteroaryl; wherein each R2a, R2b and R2c is independently selected from the group consisting of hydrogen, unsubstituted or substituted C1-4alkyl, unsubstituted or substituted C1-6alkyl, unsubstituted or substituted C3-12cycloalkyl, and C3-12 heterocycloalkyl unsubstituted or substituted; or Ra and R2b and the nitrogen atom to which they are attached bind to form unsubstituted or substituted C3-12 heterocycloalkyl or unsubstituted or substituted C3-12 heteroaryl; wherein unsubstituted or substituted C3-12 heterocycloalkyl or unsubstituted or substituted C3-12 heteroaryl has 1 to 3 heteroatoms selected from O, N, and S; W is N or CRW; wherein Rw is independently selected from the group consisting of hydrogen, C1-4 haloalkyl, unsubstituted or substituted C1-4alkyl, and unsubstituted or substituted C1-4alkoxy; R3 is hydrogen; R4 is selected from the group consisting of C1-8 haloalkyl, unsubstituted or substituted C1-4 alkyl, unsubstituted or substituted C3-8 cycloalkyl, unsubstituted or substituted C3-12 heterocycloalkyl, and unsubstituted or substituted C3-12 heteroaryl; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.